Free Trial

Aptevo Therapeutics (APVO) Stock Price, News & Analysis

-0.02 (-2.59%)
(As of 05/24/2024 08:49 PM ET)
Today's Range
50-Day Range
52-Week Range
67,000 shs
Average Volume
566,525 shs
Market Capitalization
$2.90 million
P/E Ratio
Dividend Yield
Price Target
APVO stock logo

About Aptevo Therapeutics Stock (NASDAQ:APVO)

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Stock Price History

APVO Stock News Headlines

Aptevo Therapeutics Inc (AP8N.BE)
Aptevo Therapeutics Inc (AP8N.DU)
Aptevo Therapeutics Inc (APVO)
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics GAAP EPS of -$0.50
Aptevo to Present at Bio-Europe Conference
Aptevo Therapeutics Inc
See More Headlines
Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$3.11 million
Book Value
$1.50 per share


Free Float
Market Cap
$2.90 million
Not Optionable

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Marvin L. White (Age 62)
    President, CEO & Director
    Comp: $841.39k
  • Mr. Jeffrey G. Lamothe CA (Age 58)
    Executive VP & COO
    Comp: $722.51k
  • Ms. SoYoung Kwon J.D. (Age 55)
    LL.M., Senior VP, General Counsel, Business Development & Corporate Affairs
    Comp: $639.37k
  • Ms. Daphne L. Taylor (Age 58)
    Senior VP & CFO
  • Dr. Dirk Huebner M.D. (Age 60)
    Chief Medical Officer

APVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares.
View APVO analyst ratings
or view top-rated stocks.

How have APVO shares performed in 2024?

Aptevo Therapeutics' stock was trading at $7.9640 at the beginning of the year. Since then, APVO stock has decreased by 91.1% and is now trading at $0.7110.
View the best growth stocks for 2024 here

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our APVO earnings forecast

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) released its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($22.00) earnings per share for the quarter, beating analysts' consensus estimates of ($28.16) by $6.16.

When did Aptevo Therapeutics' stock split?

Aptevo Therapeutics's stock reverse split on Wednesday, March 6th 2024. The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APVO) was last updated on 5/27/2024 by Staff

From Our Partners